FDA advisory backs Merck & Co's Gardasil for prevention of anal cancer and AIN in both men and women
The US Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee has advised that the data presented support an indication for drug giant Merck & Co’s (NYSE: MRK) Gardasil ([Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant) for the prevention of anal cancer and anal intraepithelial neoplasia (AIN) in both males and females aged nine through 26 years.
"We are pleased with the outcome of today's meeting and look forward to continued discussions with the FDA as it evaluates the data for the proposed indication," said Elizabeth Garner, director, clinical research, at Merck Research Laboratories, adding that the “discussion brings us closer to being able to also provide Gardasil to men and women for the prevention of anal cancer and AIN."
Anal cancer relatively rare in USA
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze